Risk Stratification and Prevention Strategies in Cardiomyopathies

Overview

Recent studies highlight the importance of risk stratification in cardiomyopathies to prevent sudden cardiac death and heart failure progression. Biomarkers, imaging, ECG findings, and lifestyle factors all contribute to improved prediction and management of adverse outcomes.

Background

Cardiomyopathies are associated with increased risk of arrhythmic sudden cardiac death and heart failure. Accurate risk stratification is essential to guide preventive strategies and improve patient outcomes. Biomarkers such as high-sensitivity cardiac troponins, imaging modalities like cardiac magnetic resonance, and electrocardiographic parameters provide valuable prognostic information. Additionally, modifiable lifestyle factors and pharmacologic interventions play a role in managing disease progression.

Data Highlights

Key Findings

• High-sensitivity troponins T and I levels correlate with the burden of modifiable cardiovascular risk factors and predict all-cause mortality.
• Lower BMI in non-ischaemic dilated cardiomyopathy patients is associated with worse cardiac remodeling, fibrosis, and adverse outcomes.
• Complete right bundle branch block is rare in young individuals but warrants further evaluation when present with prolonged QRS or other ECG abnormalities.
• In patients with left ventricular ring-like scar, pathological anterior Q waves, prolonged QRS duration, and increased LV end-diastolic volume predict life-threatening arrhythmic events.
• Vigorous lifelong exercise does not increase risk of LV systolic dysfunction or arrhythmias in carriers of titin variants.
• Myocardial fibrosis is prevalent in cardiometabolic conditions, especially hypertension, and is a key predictor of arrhythmic risk.
• SGLT2 inhibitors reduce all-cause mortality and heart failure hospitalizations in hypertrophic cardiomyopathy patients with diabetes.

Clinical Implications

Risk stratification in cardiomyopathies should integrate biomarker assessment, imaging, and ECG findings to identify patients at high risk for arrhythmic events and heart failure progression. Lifestyle modification targeting cardiovascular risk factors remains crucial. The use of SGLT2 inhibitors may offer additional benefit in hypertrophic cardiomyopathy patients with diabetes. ECG abnormalities such as complete RBBB in young patients should prompt further cardiac evaluation.

Conclusion

Comprehensive evaluation combining clinical, biochemical, imaging, and electrocardiographic data enhances risk prediction in cardiomyopathies, enabling tailored preventive strategies to reduce mortality and adverse cardiovascular events.

References

1. Bay et al. 2024 -- Association of modifiable lifestyle risk factors with high-sensitivity troponin T and I concentrations and clinical outcomes
2. Huang et al. 2024 -- Body mass index, regional adipose deposition, and clinical outcomes in non-ischemic dilated cardiomyopathy
3. MacLachlan et al. 2024 -- Prevalence and clinical significance of electrocardiographic complete right bundle branch block in young individuals
4. Parisi et al. 2024 -- Arrhythmic risk stratification in patients with left ventricular ring-like scar
5. Savonitto et al. 2024 -- Exercise intensity and cardiac disease development in carriers of titin variants
6. Yeo et al. 2024 -- Global prevalence of myocardial fibrosis among individuals with cardiometabolic conditions: a systematic review and meta-analysis
7. Jung et al. 2024 -- Sodium-glucose cotransporter-2 inhibitors and clinical outcomes in patients with hypertrophic cardiomyopathy and diabetes: a population-based cohort study